rimonabant(rimonabant cost) is the product launched by Sanofi-Aventis of France. This high efficacy appetite suppressant was launched in the UK anti-obesity drug market in the month of June. The drug is a ray of hope for million suffering from obesity. rimonabant cost has a chemical named Rimonabant which blocks the CB-1 receptor present in nerve cells. CB-1 receptor is the part of that mechanism which transmits hunger signals to the brain. Inhibiting working of CB-1 receptor means you will not feel enormous urge for food. In absence of food the metabolic system will burn the extra fats to get energy and an obese will get normal stature. buying, rimonabant can also curb urge for smoking.Using Rimonabant buying may have some mild initial side effects like nausea, constipation, stomach disorder and dizziness. Once the body is adjusted to the medication these problems disappear automatically. This is an oral prescription drug which must be taken on doctor’s advice.

buying rimonabant’s high efficacy in curbing dual problems i.e. obesity and smoking, therefore people are rushing for it. Sanofi-Aventis is planning to launch the drug in the US market after getting FDA approval for it.
Everyone knows that it’s the pharmaceutical industry’s job to come up with new products to cure what ails us. From Pfizer’s (NYSE: PFE) Lipitor to Eli Lilly’s (NYSE: LLY) Cialis, drugmakers have done a remarkable job of zeroing in on problems and finding treatments for them. It’s not too often, though, that pharmaceutical outfits develop medicine that addresses multiple conditions at once.Sanofi-Aventis (NYSE: SNY), though, may have done just that.The company intends to ask the Food and Drug Administration for approval to sell the drug rimonabant cost, which it plans to call rimonabant, within the next few months, the Associated Press reports. Sanofi-Aventis says that the drug allowed patients who took it for more than two years in trials to lose an average of 16 pounds. What’s more, most of the weight patients lost in the first year, they kept off.[rimonabant cost]

Of course, pharmaceutical outfits have ventured into the weight-loss field before, and it hasn’t always been pretty. Wyeth (NYSE: WYE), for instance, is still working to pay off the liability associated with the cardiovascular side effects of its fen-phen diet medication. Diet drugs on the market, meanwhile, are typically sold only for short-term use.

August 2, 2007
Sanofi-Aventis SA, the world’s third-largest pharmaceutical company, blamed competition from rivals’ generic copies of its blockbuster drugs and a weaker dollar on Wednesday as it posted a 6.3 percent decline in second-quarter profit.

LONDON, July 19, 2007-The European Medicines Agency (EMEA) today recommended contraindicating rimonabant structure (rimonabant) from sanofi-aventis, in patients with ongoing major depression or who are being treated with antidepressants, because of the risk of psychiatric side effects. Doctors in the EU have already been warned about this since June 2006 but the Agency’s Committee for Medicinal Products for Human Use (CHMP) has now recommended upgrading this warning.rimonabant structure has been authorised in the EU since June 2006 as an adjunct to diet and exercise for the treatment of obese or overweight adult patients. Psychiatric side effects, in particular depression, were identified as the main safety issue at the time of approval. They were reflected in the medicine’s product information as a warning that doctors should not prescribe rimonabant structure in patients with uncontrolled serious psychiatric conditions such as major depression.As part of its continuous monitoring of the safety of medicines, the CHMP requested sanofi-aventis in June 2007 to submit all available information on the psychiatric side effects of rimonabant structure. Finalising the assessment of the available data at its 16-19 July 2007 meeting, the CHMP concluded that the benefits of rimonabant continue to outweigh its risks, except in patients with ongoing major depression or taking antidepressants.